This Medication Is Everywhere-And It May Slow Biological Aging

Key Points:

• New research published in Nature Communications suggests that semaglutide, a GLP-1 agonist found in medications like Ozempic and Wegovy, may slow biological aging by reducing DNA markers linked to aging in adults with HIV and lipohypertrophy.
• The 32-week randomized, placebo-controlled trial showed that semaglutide slowed the pace of biological aging by 9%, with benefits observed in the blood, brain, heart, kidney, liver, and metabolic measures.
• Experts believe the anti-aging effects may be due to reduced inflammation from fat loss, improved blood sugar control, increased physical activity, and favorable epigenetic changes, though it remains unclear if weight loss or the medication itself drives these benefits.
• More research is needed to determine if GLP-1 agonists have similar effects on aging in people without underlying inflammatory conditions and whether these drugs could be used as gerotherapeutics.
• While promising, current evidence does not conclusively show that GLP-1 medications reduce aging independently of weight loss, and further studies are necessary to explore their broader potential beyond diabetes and obesity management.